Clinical Effectiveness and Safety of SHR-A1811 in Chinese Patients With HER2-Altered NSCLC

Inclusion Criteria: * Age ≥18 years at signing informed consent form (ICF). * Pathologically documented unresectable and/or metastatic NSCLC. * Documented any known activating HER2 alteration. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. * Patients who receive SHR-A1811 based on physicians' discretion (Newly received or just have started the first dose no longer than 3 months before enrollment). Exclusion Criteria: * Has spinal cord compression or clinically active CNS metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. * Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension active bleeding diatheses, etc.